Indication
Sickle Cell Disease
186 clinical trials
145 products
20 drugs
Product
BEAM-101Clinical trial
A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) to Increase Fetal Hemoglobin (HbF) Production in Patients With Severe Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-02-01
Product
InclacumabClinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive CrisesStatus: Active (not recruiting), Estimated PCD: 2024-08-15
Product
VoxelotorClinical trial
A First-in-patient Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Subjects With Severe Complications of Sickle Cell DiseaseStatus: Active (not recruiting), Estimated PCD: 2025-08-19
Product
PlaceboClinical trial
An Open Label Extension Study of Voxelotor (GBT440) Administered Orally to Participants With Sickle Cell Disease Who Have Participated in Voxelotor Clinical TrialsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
BRL-101Clinical trial
Clinical Study on the Safety and Efficacy of a Single Intravenous Dose of CRISPR/Cas9-Edited Autologous CD34+ Hematopoietic Stem/Progenitor Cells (BRL-101) in the Treatment of Sickle Cell DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-08-20
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive CrisesStatus: Terminated, Estimated PCD: 2023-11-24
Clinical trial
A Long-term Follow-up Study of Subjects With β-thalassemia or Sickle Cell Disease Treated With Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)Status: , Estimated PCD: 2039-09-01
Product
OTQ923Product
CTX001Clinical trial
An Open Label, Single Arm, Multicenter Study to Evaluate the Effect of Voxelotor on Cerebral Blood Flow and Neurocognitive Function in Adolescents and Adults With Sickle Cell DiseaseStatus: Withdrawn, Estimated PCD: 2023-08-23
Product
crizanlizumabProduct
BupropionProduct
RepaglinideProduct
FlurbiprofenProduct
OmeprazoleProduct
MidazolamProduct
MetforminProduct
FurosemideProduct
RosuvastatinClinical trial
A Phase 1, Open-Label, Two-Part, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Voxelotor on the Pharmacokinetics of Selected CYP and Transporter Probe Substrates in Healthy ParticipantsStatus: Completed, Estimated PCD: 2023-10-04
Clinical trial
Managed Access Program (MAP) Cohort Treatment Plan CSEG101A2001M to Provide Access to Crizanlizumab for Sickle Cell Disease Patients With History of Vaso-occlusive CrisisStatus:
Clinical trial
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-08-01
Product
EDIT-301Product
Nula-CelClinical trial
A Phase I/II Study of Nula-cel in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2026-07-31
Clinical trial
Clinical Study on the Safety and Efficacy of a Single Intravenous Dose of CRISPR/Cas9-Edited Autologous CD34+ Hematopoietic Stem/Progenitor Cells (BRL-101) in the Treatment of Sickle Cell DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-10-20
Product
OxbrytaClinical trial
A Retrospective Data Collection and Analysis Study of Patients With Sickle Cell Disease (SCD) Who Have Been Treated With Oxbryta® (Voxelotor)Status: Completed, Estimated PCD: 2022-02-25
Product
DeferiproneClinical trial
Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other AnemiasStatus: Terminated, Estimated PCD: 2019-04-30
Product
VIT-2763Clinical trial
A Phase 2a, Double-blind, Randomised, Placebo-controlled, Efficacy, and Safety Study of Multiple Doses of VIT-2763 in Subjects With Sickle Cell DiseaseStatus: Completed, Estimated PCD: 2024-03-07
Clinical trial
A Phase 1/2/3 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Severe Sickle Cell DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-02-01
Product
Exa-celClinical trial
A PHASE 1 STUDY TO ASSESS THE MASS BALANCE, EXCRETION, AND PHARMACOKINETICS OF [14C]-GBT021601, AN ORAL HEMOGLOBIN SPOLYMERIZATION INHIBITOR, IN HEALTHY PARTICIPANTSStatus: Completed, Estimated PCD: 2023-08-10
Product
GBT021601Clinical trial
A Phase 3 Study to Evaluate Efficacy and Safety of a Single Dose of Exa-cel in Subjects With Severe Sickle Cell Disease, βS/βC GenotypeStatus: Not yet recruiting, Estimated PCD: 2029-12-01
Clinical trial
An Open-label Extension Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Who Have Participated in an Inclacumab Clinical TrialStatus: Recruiting, Estimated PCD: 2028-11-15
Clinical trial
An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Vaso-occlusive Crises.Status: Completed, Estimated PCD: 2024-02-14
Product
EtavopivatClinical trial
A Pilot Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-06-15
Product
TAK-755Clinical trial
A Phase 1 Randomized, Double-blind, Placebo-controlled, Multicenter, Ascending Dose, Safety and PK/PD Study of SHP655 (rADAMTS13) in Sickle Cell Disease at Baseline HealthStatus: Completed, Estimated PCD: 2022-10-26
Product
EpeleutonClinical trial
An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of Etavopivat in Patients With Thalassemia or Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-11-03
Product
Nula-celClinical trial
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary StrokeStatus: Recruiting, Estimated PCD: 2025-01-31
Product
HydroxyureaProduct
Oxbryta (voxelotor)Product
MGTA-145Product
PlerixaforClinical trial
A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of MGTA-145 in Combination With Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients With Sickle Cell DiseaseStatus: Terminated, Estimated PCD: 2022-12-08
Clinical trial
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects With Sickle Cell Disease (SCD)Status: Recruiting, Estimated PCD: 2025-04-01
Product
FTX-6058Clinical trial
A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Sickle Cell Patients With Vaso-Occlusive CrisisStatus: Completed, Estimated PCD: 2023-06-26
Clinical trial
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 2, Open-label, Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and NephropathyStatus: Not yet recruiting, Estimated PCD: 2026-05-01
Product
MitapivatClinical trial
An Open-label Extension Study to Evaluate the Long-term Safety of GBT021601 Administered to Participants With Sickle Cell Disease Who Have Participated in a GBT021601 Clinical TrialStatus: Recruiting, Estimated PCD: 2029-04-11
Clinical trial
An Open-Label Extension Study of Voxelotor Administered Orally to Participants With Sickle Cell Disease Who Have Participated in Voxelotor Clinical TrialsStatus: Recruiting, Estimated PCD: 2028-03-04
Clinical trial
A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants With Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2026-10-02
Product
OsivelotorProduct
NDecClinical trial
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral Etavopivat, a Pyruvate Kinase Activator in Patients With Sickle Cell Disease (HIBISCUS)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized Double-Blind Phase IIA Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD)Status: Recruiting, Estimated PCD: 2024-07-26
Product
CrovalimabProduct
bb1111Clinical trial
A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the BB305 Lentiviral Vector in Subjects With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients With Sickle Cell DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-06-26
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)Status: Active (not recruiting), Estimated PCD: 2023-08-24
Clinical trial
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell DiseaseStatus: Completed, Estimated PCD: 2023-07-31
Clinical trial
Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment OptionsStatus:
Clinical trial
A Randomized, Placebo-controlled, Double Blind, Single Ascending and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of FT-4202 in Healthy Volunteers and Sickle Cell Disease PatientsStatus: Completed, Estimated PCD: 2021-12-17
Clinical trial
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2026-01-20
Product
FT-4202/PlaceboProduct
CSL889Product
NicotinamideClinical trial
A 2-Part, Phase 1, Multi-Center, Single-Dose, Open Label, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CSL889 in Adult Patients With Sickle Cell DiseaseStatus: Completed, Estimated PCD: 2023-07-24
Product
HydroxycarbamideClinical trial
An Open-label, Non-comparative, Multicentre Study to Evaluate the Acceptability of a New Paediatric Formulation of Hydroxycarbamide in Children With Sickle Cell Disease.Status: Completed, Estimated PCD: 2022-10-28
Clinical trial
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single-and Multiple-Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics, With an Open-Label Initial Food Effect and CYP3A Drug-Drug Interaction Study, of FTX-6058 in Healthy Adult Subjects, and a Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study Evaluating, Safety, Tolerability and Pharmacokinetics in Subjects With Sickle Cell Disease (SCD)Status: Completed, Estimated PCD: 2022-11-15
Clinical trial
Proof-of-concept Study of Nicotinamide and Oral Tetrahydrouridine (THU) and Decitabine to Treat High Risk Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2024-03-08
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose (SAD/MAD) Study to Evaluate the Safety, Tolerability, PK, and Food Effect of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Healthy Participants.Status: Completed, Estimated PCD: 2022-11-02
Product
IMR-687Clinical trial
A Phase 2b Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects With Sickle Cell DiseaseStatus: Terminated, Estimated PCD: 2022-03-02
Product
IW-1701Clinical trial
A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients With Stable Sickle Cell DiseaseStatus: Completed, Estimated PCD: 2020-07-22
Clinical trial
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - ExtensionStatus: Recruiting, Estimated PCD: 2025-08-21
Clinical trial
An Open-Label, Expanded Access Protocol for Patients With Sickle Cell Disease Who Have No Alternative Treatment OptionsStatus:
Product
CrizanlizuambClinical trial
A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)Status: Completed, Estimated PCD: 2023-03-20
Clinical trial
An Intrapatient Single Dose and Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of GBT021601, a Hemoglobin S Polymerization Inhibitor, in Participants With Sickle Cell Disease (SCD)Status: Completed, Estimated PCD: 2022-12-06
Product
Standard of CareProduct
CrizanlizumabClinical trial
A Phase 1a Study of IMR-687 in Healthy Adult VolunteersStatus: Completed, Estimated PCD: 2017-07-08
Clinical trial
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)Status: Completed, Estimated PCD: 2020-08-28
Clinical trial
An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab StudyStatus: Recruiting, Estimated PCD: 2031-10-27
Clinical trial
Part A: Phase IB, Single Site, Dose-Escalation of SCD-101 and Part B: Randomized, Double-Blind, Placebo-Controlled Crossover of SCD-101 in Adults With Homozygous Sickle Cell Disease or S/Beta 0 Thalassemia.Status: Active (not recruiting), Estimated PCD: 2023-11-01
Product
ALXN1820Product
SCD-101Clinical trial
A Phase 2a, Randomized, Open-Label Study to Evaluate Multiple Dosing Regimens of Subcutaneous ALXN1820 in Adult Participants With Sickle Cell DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-06-24
Clinical trial
A Phase 2, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Voxelotor in Patients With Sickle Cell DiseaseStatus: Terminated, Estimated PCD: 2021-06-08
Clinical trial
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell DiseaseStatus: Completed, Estimated PCD: 2023-09-04
Product
RifaximinClinical trial
Multicentre Randomized Double-blind Placebo-controlled Study to Evaluate the Effect on Albuminuria of 6 Months Treatment With Hydroxycarbamide (Siklos®) or a Placebo in Adults With Sickle Cell Disease:Status: Recruiting, Estimated PCD: 2024-06-01
Product
High Dose RifaximinProduct
voxelotorClinical trial
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell DiseaseStatus: Completed, Estimated PCD: 2019-10-08
Clinical trial
A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell DiseaseStatus: Active (not recruiting), Estimated PCD: 2025-07-14
Product
BusulfanProduct
BIVV003Clinical trial
A Phase 4, Multicenter, Open-label Study to Evaluate the Treatment Effect of Voxelotor on Physical Activity in Adolescents and Adults With Sickle Cell DiseaseStatus: Completed, Estimated PCD: 2022-09-08
Clinical trial
A Phase 1/2, Open-Label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AB1 in Adult Patients With Sickle Cell Disease (SCD)Status: Recruiting, Estimated PCD: 2024-11-01
Product
AB1Clinical trial
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals With Higher Risk of Transplant FailureStatus: Recruiting, Estimated PCD: 2023-12-31
Product
AlemtuzumabProduct
SirolimusDrug
cyclophosphamideProduct
PentostatinClinical trial
A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the Sickle Cell Disease by Transplantation of an Autologous CD34+ Enriched Cell Fraction That Contains CD34+ Cells Transduced ex Vivo With the GLOBE1 Lentiviral Vector Expressing the βAS3 Globin Gene (GLOBE1 βAS3 Modified Autologous CD34+ Cells) in Patients With Sickle Cell Disease (SCD)Status: Active (not recruiting), Estimated PCD: 2022-07-28
Product
DREPAGLOBEClinical trial
IMatinib for PAin in Chronic Treatment of Sickle Cell Anemia (IMPACT SCA): A Pilot Study of Imatinib in Patients With Sickle Cell Anemia and Recurrent Vaso-occlusive PainStatus: Recruiting, Estimated PCD: 2025-09-01
Product
ImatinibClinical trial
Evaluation of the Diagnostic Performance of Non-Invasive Prenatal Diagnosis for Single Gene DisordersStatus: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease. (BMTCTN1507)Status: Active (not recruiting), Estimated PCD: 2024-09-01
Drug
hydroxyureaProduct
Rabbit-ATGProduct
ThiotepaProduct
FludarabineProduct
MesnaClinical trial
Kinetics of Donor Red Blood Cell Survival in Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS): A Pilot StudyStatus: Recruiting, Estimated PCD: 2024-06-01
Product
RivaroxabanClinical trial
Zinc Supplementation in Sickle Cell Disease: A Precursor to the 'Think Zinc for Bones' TrialStatus: Not yet recruiting, Estimated PCD: 2026-09-30
Product
ZincClinical trial
A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-AID)Status: Recruiting, Estimated PCD: 2028-07-01
Drug
rapamycinClinical trial
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell DiseaseStatus: Active (not recruiting), Estimated PCD: 2026-11-30
Clinical trial
Safety and Efficacy of Glutamine in Preventing Vaso-occlusive Crisis Among Sickle Cell Disease Patients: Randomized Controlled StudyStatus: Completed, Estimated PCD: 2023-01-03
Product
L-GlutamineClinical trial
Suitability of Periarticular Steroid Injections for Sickle Cell Arthropathy Pain TherapyStatus: Completed, Estimated PCD: 2023-03-31
Product
DexamethasoneClinical trial
Realizing Effectiveness Across Continents With Hydroxyurea: A Phase I/II Prospective Trial of Hydroxyurea for Children With Sickle Cell AnemiaStatus: Recruiting, Estimated PCD: 2027-10-04
Clinical trial
A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2024-12-31
Product
BenserazideClinical trial
Hematopoietic Stem Cell Transplant for Sickle Cell DiseaseStatus: Completed, Estimated PCD: 2023-02-17
Clinical trial
Non-myeloablative Phase I/II Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ FunctionStatus: Recruiting, Estimated PCD: 2032-09-01
Clinical trial
Positron Emission Tomography (PET) Imaging of Vaso-occlusive Crisis(VOC) in Sickle Cell Disease (SCD).Status: Recruiting, Estimated PCD: 2025-12-31
Product
Cu-64]-LLP2AClinical trial
Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell DiseaseStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Drug
PlerixaforClinical trial
Use of Metformin as a Fetal Hemoglobin Inducer in Patients With HemoglobinopathiesStatus: Completed, Estimated PCD: 2020-07-20
Drug
MetforminClinical trial
A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem CellsStatus: Active (not recruiting), Estimated PCD: 2023-08-28
Clinical trial
Allogeneic Stem Cell Transplantation for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion - NYMC 588Status: Recruiting, Estimated PCD: 2025-12-31
Product
Alpha Beta DepletionClinical trial
BrUOG 419 - Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa (PUSHUP)Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Pilot Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) as a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)Status: Recruiting, Estimated PCD: 2025-12-31
Drug
MotixafortideProduct
NatalizumabClinical trial
A Phase II Study to Determine the Safety of Defibrotide in Sickle Cell Disease-Related Acute Chest SyndromeStatus: Completed, Estimated PCD: 2022-07-01
Product
DefibrotideClinical trial
A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-11-01
Product
ATGDrug
fludarabineClinical trial
Population Pharmacokinetics and Pharmacodynamics of Thiotepa and TEPA in Pediatric Patients Undergoing Hematopoietic Cell Transplantation (HCT).Status: Completed, Estimated PCD: 2023-07-31
Clinical trial
Low Dose Aspirin for Preventing Intrauterine Growth Restriction and Preeclampsia in Sickle Cell Pregnancy (PIPSICKLE): a Randomized Controlled TrialStatus: Active (not recruiting), Estimated PCD: 2024-11-30
Product
AspirinClinical trial
Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease (SCD) and B-ThalassemiaStatus: Active (not recruiting), Estimated PCD: 2023-01-20
Clinical trial
An Evaluation of the Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET (Stress-Rest) Myocardial Perfusion Imaging (MYPERS)Status: Recruiting, Estimated PCD: 2025-09-01
Product
[13N]NH3Product
LexiscanClinical trial
A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-02-01
Product
AlendronateClinical trial
Chronobiology and Chronopharmacology to Prevent Sickle Cell Kidney DiseaseStatus: Terminated, Estimated PCD: 2021-02-01
Drug
LosartanClinical trial
Randomized Trial Evaluating Lidocaine Intravenous in the Emergency Department For Sickle Cell Crisis - RELIEF-SCCStatus: Not yet recruiting, Estimated PCD: 2025-01-02
Product
LidocaineClinical trial
A Study to Evaluate the Effects of Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell DiseaseStatus: Completed, Estimated PCD: 2022-06-13
Product
IsoquercetinClinical trial
A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) Versus Placebo, With or Without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Frequent Vaso-Occlusive CrisesStatus: Not yet recruiting, Estimated PCD: 2029-03-23
Clinical trial
Safety and Efficacy of Monthly High-Dose Vitamin D3 Supplementation in Children and Adolescents With Sickle Cell Disease and Healthy Counter ParentsStatus: Completed, Estimated PCD: 2024-01-30
Drug
Vitamin D3Clinical trial
Phase I Study to Determine the Safety and Tolerability of Escalating Doses of Panobinostat (LBH589) in Patients With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-12-01
Drug
panobinostatClinical trial
A Phase I Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell DiseaseStatus: Not yet recruiting, Estimated PCD: 2024-08-31
Product
FostamatinibClinical trial
A Phase IB Randomized, Placebo-Controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Patients With Sickle Cell Disease (SCD)Status: Recruiting, Estimated PCD: 2025-01-14
Clinical trial
A Pilot Study of Pre-transplant Immunosuppressive Therapy for Haploidentical Transplants in Patients With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-03-19
Clinical trial
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach: Adding Daratumumab for Patients With Anti-donor Red Cell AntibodYStatus: Recruiting, Estimated PCD: 2044-09-01
Product
DaratumumabClinical trial
A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Disease and Other HemoglobinopathiesStatus: Active (not recruiting), Estimated PCD: 2023-11-01
Product
ThymoglobulinProduct
CyclophosphamideProduct
Mycophenolate mofetilClinical trial
A Pilot Study of Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney DiseaseStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)Status: Recruiting, Estimated PCD: 2025-12-31
Product
Red Blood CellClinical trial
REALIZING EFFECTIVENESS ACROSS CONTINENTS WITH HYDROXYUREA (REACH): A PHASE I/II PILOT STUDY OF HYDROXYUREA FOR CHILDREN WITH SICKLE CELL ANEMIAStatus: Active (not recruiting), Estimated PCD: 2018-07-01
Clinical trial
Evaluation of the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of MitapivatStatus: Active (not recruiting), Estimated PCD: 2028-02-28
Clinical trial
Early HLA Matched Sibling Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: A Sickle Transplant Advocacy and Research Alliance (STAR) TrialStatus: Recruiting, Estimated PCD: 2027-01-01
Drug
MelphalanClinical trial
Minimizing Toxicity in HLA-identical Related Donor Transplantation for Children With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Pilot Study To Evaluate The Safety And Feasibility of Hematopoietic Progenitor Cell Mobilization With Plerixafor as Part of a Gene Therapy Strategy in Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2024-09-06
Clinical trial
CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplantation for Non-Malignant DiseaseStatus: Active (not recruiting), Estimated PCD: 2030-02-01
Clinical trial
Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Using PlerixaforStatus: Completed, Estimated PCD: 2019-02-27
Clinical trial
HEMolyse and Organ Damage imPROvement in Sickle Cell Disease by VoxElotor. An Open-label One Stage Phase II DesignStatus: Recruiting, Estimated PCD: 2024-03-22
Clinical trial
Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients With COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic TransplantStatus: Active (not recruiting), Estimated PCD: 2024-11-17
Product
TacrolimusProduct
MycophenolateClinical trial
A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)Status: Active (not recruiting), Estimated PCD: 2022-08-31
Drug
VarlilumabClinical trial
Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute PainStatus: Recruiting, Estimated PCD: 2025-12-01
Product
Immune GlobulinClinical trial
Minocycline In Neurocognitive Outcomes - Sickle Cell DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Product
MinocyclineClinical trial
Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade)Status: Completed, Estimated PCD: 2008-10-01
Product
DeferoxamineProduct
DeferasiroxClinical trial
Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Product
Bone marrow transplantClinical trial
Safety and Efficacy of Prophylactic Defibrotide in Children, Adolescents, and Young Adults With Sickle Cell Disease or Beta Thalassemia Following MAC and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) AddbackStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
The Evaluation of the Safety and Efficacy of Sustained Release Dexamethasone Intracanalicular Insert (DEXTENZA) in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (TENDER)Status: Recruiting, Estimated PCD: 2024-04-01
Product
DextenzaProduct
Pred ForteClinical trial
Dronabinol for the Reduction of Chronic Pain and Inflammation in People With Sickle Cell DiseaseStatus: , Estimated PCD: 2026-06-01
Product
DronabinolClinical trial
Clinical Research Study of Autologous Stem Cell Transplantation for Sickle Cell Disease (SCD) Using Peripheral Blood CD34+ Cells Modified With the Lenti/G-βAS3-FB Lentiviral VectorStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell DiseaseStatus: Active (not recruiting), Estimated PCD: 2023-07-27
Drug
sirolimusClinical trial
Assessing Combination Hydroxyurea and Exogenous Erythropoietin in Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2024-11-01
Product
Epoetin AlfaClinical trial
PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant DisordersStatus: Completed, Estimated PCD: 2022-02-17
Product
campathProduct
pentostatinClinical trial
The Role of Metabolic and Hemodynamic Reserve in Age-Related Brain Vulnerability in Pediatric Sickle Cell AnemiaStatus: Recruiting, Estimated PCD: 2026-03-31
Product
Carbon DioxideClinical trial
Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone MarrowStatus: Completed, Estimated PCD: 2021-12-12
Clinical trial
A Single-centre, Open-label, Randomised, Single-dose, Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of Etavopivat in Healthy ParticipantsStatus: Recruiting, Estimated PCD: 2024-07-06
Clinical trial
Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients (RBC-IMPACT)Status: Completed, Estimated PCD: 2024-03-31
Product
Red Blood Cell TransfusionClinical trial
Effects of the Contraceptive Implant in Women With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-02-15
Product
NexplanonClinical trial
Reduced Intensity Related Donor Peripheral Blood Derived Hematopoietic Progenitor Cell Transplantation for Patients With Severe Sickle Cell DiseaseStatus: , Estimated PCD: 2024-07-01
Clinical trial
A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant DisordersStatus: Recruiting, Estimated PCD: 2024-04-01
Product
RIC regimenProduct
GVHD prophylaxis regimenClinical trial
Red Cell Half Life Determination in Patients With and Without Sickle Cell DiseaseStatus: Completed, Estimated PCD: 2022-12-20
Product
BiotinClinical trial
Arginine Therapy for the Treatment of Vaso-Occlusive Events in Children With Severe Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2024-07-01
Product
ArginineClinical trial
Phase 2 Randomized Control Trial of Arginine Therapy for Pediatric Sickle Cell Disease PainStatus: Completed, Estimated PCD: 2021-02-21
Product
L-arginineClinical trial
Evaluation of Vitamin D Deficiency Distribution in Children With Sickle Cell Disease Followed in Lyon, FranceStatus: Completed, Estimated PCD: 2022-02-03
Product
25-OH Vitamin DClinical trial
Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2Status: Completed, Estimated PCD: 2023-05-31
Product
MometasoneClinical trial
Preservation and Transfer of Hepatitis B Virus Immunity After Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Adult Sickle Cell Disease Patients (Protect Study)Status: Recruiting, Estimated PCD: 2024-01-01
Product
Engerix-BClinical trial
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive CrisisStatus: Recruiting, Estimated PCD: 2025-01-02
Clinical trial
RH Genotype Matched Red Cell Transfusions for Patients With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2029-04-01
Clinical trial
Advantage of Clonidine With Morphine In Patient Controlled Analgesia Pump for the Treatment of Vaso-occlusive Crisis in Sickle Cell Disease PatientsStatus: Recruiting, Estimated PCD: 2023-12-31
Product
ClonidineClinical trial
Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell AnemiaStatus: Not yet recruiting, Estimated PCD: 2028-07-01
Clinical trial
Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Sickle Cell DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-05-13
Clinical trial
Low-Dose Tocilizumab for Acute Chest Syndrome in Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-04-01
Drug
TocilizumabClinical trial
A Pilot Study of Nonmyeloablative Regimen Using Total Marrow and Lymphoid Irradiation for Irradiation Sparing of Bystander Organs in Hematopoietic Cell Transplantation From Matched Related or Unrelated Donor in Patients With Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2028-10-26
Drug
alemtuzumabClinical trial
Cerebrovascular Reserve and White Matter Disease in Patients With Chronic AnemiaStatus: Completed, Estimated PCD: 2022-12-31
Product
AcetazolamideClinical trial
Sickle Cell Disease Treatment With Arginine Therapy (STArT) TrialStatus: Recruiting, Estimated PCD: 2027-04-01
Product
Arginine HydrochlorideClinical trial
A Prospective, Randomized Controlled Study to Evaluate the Effects of Daily Low Dose Aspirin in Pregnant Women With Sickle Cell Disease When Initiated at the First Trimester Versus the Second Trimester of the Gestational PeriodStatus: Recruiting, Estimated PCD: 2025-03-16
Clinical trial
Sickle Cell Disease Stem Cell Mobilization and Apheresis Using MotiixafortideStatus: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Phase 3b, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Treatment Effect of Voxelotor on Neurocognitive Function in Pediatric Participants 8 to < 18 Years of Age With Sickle Cell DiseaseStatus: Terminated, Estimated PCD: 2022-09-30
Clinical trial
Daily Vitamin D for Sickle-cell Respiratory ComplicationsStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Product
Vitamin D3Clinical trial
Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet VelocityStatus: Recruiting, Estimated PCD: 2024-09-01
Product
L-ArginineClinical trial
Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using PlerixaforStatus: Withdrawn, Estimated PCD: 2023-04-01
Clinical trial
Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease: A Prospective, Phase II Study.Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-06-01
Product
CRISPR_SCD001Clinical trial
Hydroxyurea Optimization Through Precision Study (HOPS): A Prospective, Multi-center, Randomized Trial of Personalized, Pharmacokinetics-guided Dosing of Hydroxyurea Versus Standard Weight-based Dosing for Children With Sickle Cell Anemia.Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Multi-Center, Phase 2 Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell (GRASP, BMT CTN 2001)Status: Recruiting, Estimated PCD: 2026-05-01
Product
Autologous CD34+ HSC cellsClinical trial
Do Serum Alemtuzumab Concentrations Predict Donor T Cell Chimerism After Non-Myeloablative Matched Sibling Donor Stem Cell Transplantation in Sickle Cell Disease PatientsStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Pilot Study of Vitamin D Therapy to Prevent Respiratory Complications in Children With Sickle Cell DiseaseStatus: Completed, Estimated PCD: 2011-06-01
Clinical trial
Evaluation of the Efficacy of Intra-nasal Sufentanil for Analgesia of Vaso-occlusive Crisis in Sickle-cell Adults.Status: Recruiting, Estimated PCD: 2024-01-01
Product
SufentanilProduct
EMONOClinical trial
COVID-19 Vaccine Response in People Living With Sickle Cell DiseaseStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Product
COVID-19 VaccineClinical trial
Assessing Functional Capacity in Sickle Cell Patients Receiving VoxelotorStatus: Recruiting, Estimated PCD: 2024-11-23
Clinical trial
Inhaled Nitric Oxide for Pediatric Painful Sickle CrisisStatus: Terminated, Estimated PCD: 2013-08-01
Product
Nitric oxideProduct
oxygenClinical trial
Pre-Transplant Immunosuppression and Related Haploidentical Hematopoietic Cell Transplantation for Patients With Severe HemoglobinopathiesStatus: Withdrawn, Estimated PCD: 2022-12-05
Drug
bortezomibDrug
lenalidomideClinical trial
Risk Stratification for Clinical Severity of Sickle Cell Disease in Nigeria and Assessment of Efficacy and Safety During Treatment With HydroxyureaStatus: Completed, Estimated PCD: 2017-09-01
Clinical trial
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent DisordersStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell DiseasesStatus: Completed, Estimated PCD: 2022-05-04
Product
RiociguatClinical trial
Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients With Sickle Cell Disease and ThalassemiaStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Stroke Prevention in Young Adults With Sickle Cell AnemiaStatus: Active (not recruiting), Estimated PCD: 2029-06-01
Clinical trial
Endothelial Monocyte-activating Polypeptide-II as an Endothelial Dysfunction Marker and Its Relation to the Oxidative Stress in Egyptian Sickle PatientsStatus: Completed, Estimated PCD: 2023-05-01
Product
Vitamin EClinical trial
Lentiviral Vector Gene Therapy in Sickle Cell Disease Using Autologous CD34+ Hematopoietic Stem Cells Collected Via Apheresis and Modified With a Lentiviral VectorStatus: Not yet recruiting, Estimated PCD: 2025-11-10
Clinical trial
Primary Prevention of Stroke in Children With Sickle Cell Anaemia in Nigeria: Community vs Teaching HospitalStatus: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
Inflammation, Platelets and Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-11-30
Product
Blood samplingClinical trial
Familial Haploidentical T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (IND 14359)Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Phase I/II Study of Allogeneic Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease (SCD)Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
An Open-label, Multi-centre, Rollover Study to Characterise Long-term Safety and Efficacy of Etavopivat in Adults, Adolescents and Children Who Have Sickle Cell Disease or Thalassaemia and Have Completed a Treatment Period in an Etavopivat StudyStatus: Not yet recruiting, Estimated PCD: 2029-11-30
Clinical trial
Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research TrialStatus: Completed, Estimated PCD: 2021-12-30
Product
DiphenhydramineProduct
AcetaminophenProduct
MethylprednisoloneProduct
MeperidineDrug
ThiotepaProduct
CyclosporineDrug
DocetaxelProduct
AbataceptClinical trial
Effect of Adenosine 2A Receptor Agonist Regadenoson on Microvascular Blood Flow in Sickle Cell AnemiaStatus: Completed, Estimated PCD: 2019-07-05
Product
Regadenoson infusion